Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
January 23, 2019updated 07 Aug 2019 2:55pm

Concert completes enrolment of final cohort in alopecia drug trial

Concert Pharmaceuticals has completed the enrolment of the final cohort of patients in its Phase IIa trial evaluating CTP-543 for the treatment of adults with moderate-to-severe alopecia areata.

Concert Pharmaceuticals has completed the enrolment of the final cohort of patients in its Phase IIa trial evaluating CTP-543 for the treatment of adults with moderate-to-severe alopecia areata.

Alopecia areata is an autoimmune disease that leads to partial or complete loss of hair on the scalp and body.

Concert is expected to investigate twice daily dose of 12mg CTP-543 in the final cohort.

The company previously studied a 4mg and 8mg twice daily dose of CTP-543 in comparison with placebo.

Data from the trial is expected to be unveiled in the third quarter of this year.

“It is important early on in our development programme to identify the safest and most effective doses of CTP-543.”

Concert Pharmaceuticals chief development officer James Cassella said: “It is important early on in our development programme to identify the safest and most effective doses of CTP-543 for patients with a chronic autoimmune disease like alopecia areata.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

“The evaluation of the twice-daily 12mg dose provides a comprehensive exploration of the relevant dose range for CTP-543 and positions us well for later stage development of the compound.”

The Phase IIa trial features a double-blind, placebo-controlled, sequential dose design and is intended to assess the safety and efficacy of CTP-543 among alopecia areata patients.

Patients have been sequentially randomised to be treated with one of three doses of CTP-543 or placebo twice daily.

The trial’s primary outcome will be measured using the severity of alopecia tool (SALT) after 24 weeks of dosing.

Concert revealed positive interim topline results from the 4mg and 8mg twice daily cohorts in November last year.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU